Skip to main content

FDA Grants Emergency Use Authorization for MatMaCorp Coronavirus Test

NEW YORK — The US Food and Drug Administration last week granted Emergency Use Authorization for a PCR-based SARS-CoV-2 test developed by MatMaCorp.

The MatMaCorp COVID-19 2SF Test is designed to detect SARS-CoV-2 nucleic acid in upper respiratory specimens including nasopharyngeal swabs and anterior nasal swabs collected by a healthcare provider.

The test runs on the Lincoln, Nebraska-based company's Solas 8 portable nucleic acid analysis system and may be used by any lab CLIA-certified to perform high-complexity tests, according to the FDA.

Earlier this year, MatMaCorp received funding from the National Institutes of Health under its Rapid Acceleration of Diagnostics initiative to support the development of its SARS-CoV-2 test.